Seven Fleet Capital Management LP Purchases Shares of 40,000 Compass Pathways PLC Sponsored ADR $CMPS

Seven Fleet Capital Management LP acquired a new position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 40,000 shares of the company’s stock, valued at approximately $276,000.

A number of other large investors have also recently made changes to their positions in the business. RTW Investments LP raised its holdings in shares of Compass Pathways by 0.6% during the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock valued at $60,426,000 after acquiring an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC increased its position in Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after purchasing an additional 1,350,698 shares during the period. Millennium Management LLC increased its position in Compass Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after purchasing an additional 774,090 shares during the period. Toronto Dominion Bank increased its position in Compass Pathways by 152.9% during the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after purchasing an additional 1,529,013 shares during the period. Finally, ARK Investment Management LLC raised its holdings in Compass Pathways by 1.6% in the 4th quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after purchasing an additional 34,894 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CMPS has been the subject of several research analyst reports. Wall Street Zen raised shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. B. Riley Financial began coverage on shares of Compass Pathways in a research note on Friday, April 24th. They issued a “buy” rating and a $17.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Maxim Group raised their price objective on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Finally, Royal Bank Of Canada lifted their price objective on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Compass Pathways presently has an average rating of “Moderate Buy” and an average price target of $21.36.

Compass Pathways Stock Performance

Shares of Compass Pathways stock opened at $12.53 on Friday. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.69 billion, a P/E ratio of -3.98 and a beta of 2.50. The business has a fifty day simple moving average of $10.09 and a two-hundred day simple moving average of $7.81. Compass Pathways PLC Sponsored ADR has a 12 month low of $2.25 and a 12 month high of $14.76.

Compass Pathways (NASDAQ:CMPS) last announced its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. On average, equities analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.